Passengers' injuries reflected carriage interior at the railway accident in Mundelstrup, Denmark.

L. Ilkjaer,T. Lind

DOI: https://doi.org/10.1016/S0001-4575(00)00032-4

2001-03-01

Abstract:

What problem does this paper attempt to address?

Biotechnological Production of 2′-Fucosyllactose: A Prevalent Fucosylated Human Milk Oligosaccharide

Wenting Zhou,Hong Jiang,Lili Wang,Xingxing Liang,Xiangzhao Mao

DOI: https://doi.org/10.1021/acssynbio.0c00645

IF: 5.249

2021-03-09

ACS Synthetic Biology

Abstract:Human milk oligosaccharide (HMO) is a key component of human milk carbohydrates and is closely related to the nutrition and health benefits of breastfeeding in infants. 2′-Fucosyllactose (2′-FL) is the most abundant fucosylated HMO, which has remarkable value in nutrition and medicine, such as suppressing pathogen infection, regulating intestinal flora, and boosting immunity. However, 2′-FL production via the method of extraction or chemical synthesis cannot meet its large demand, and as a result, environmentally friendly and efficient biotechnological approaches, including in vitro enzymatic synthesis and microbial cell factory production, have been developed and applied to its commercialized production. This review introduces, summarizes, and discusses the recent advances in the biotechnological production of 2′-FL. Furthermore, future research directions for the biotechnological production of 2′-FL as well as the strategies to further improve its concentration are highlighted and discussed.This article has not yet been cited by other publications.

biochemical research methods
Recent advances on 2'-fucosyllactose: physiological properties, applications, and production approaches

Yingying Zhu,Li Wan,Wen Li,Dawei Ni,Wenli Zhang,Xin Yan,Wanmeng Mu

DOI: https://doi.org/10.1080/10408398.2020.1850413

Abstract:The trisaccharide, 2'-fucosyllactose (Fucα1-2Galβ1-4Glc; 2'-FL), is the most abundant oligosaccharide in human milk. It has numerous significant biological properties including prebiotics, antibacterial, antiviral, and immunomodulating effects, and has been approved as "generally recognized as safe" (GRAS) by the Food and Drug Administration (FDA) and as a novel food (NF) by the European Food Safety Authority (EFSA). 2'-FL not only serves as a food ingredient added in infant formula, but also as a dietary supplement and medical food material in food bioprocesses. There is considerable commercial interest in 2'-FL for its irreplaceable nutritional applications. This review aims at systematically elaborating key functional properties of 2'-FL as well as its applications. In addition, several approaches for 2'-FL production are described in this review, including chemical, chemo-enzymatical, and cell factory approaches, and the pivotal research results also have been summarized. With the rapid development of metabolic engineering and synthetic biology strategies, using the engineered cell factory for 2'-FL large-scale production might be a promising approach. From an economic and safety point of view, microbial selection for cell factory engineering in 2'-FL bioprocess also should be taken into consideration.
Metabolic engineering strategies of de novo pathway for enhancing 2′‐fucosyllactose synthesis in Escherichia coli

Mengli Li,Chenchen Li,Miaomiao Hu,Tao Zhang

DOI: https://doi.org/10.1111/1751-7915.13977

2021-11-29

Microbial Biotechnology

Abstract:2'-Fucosyllactose (2'-FL), one of the most abundant human milk oligosaccharides (HMOs), is used as a promising infant formula ingredient owing to its multiple health benefits for newborns. However, limited availability and high-cost preparation have restricted its extensive use and intensive research on its potential functions. In this work, a powerful Escherichia coli cell factory was developed to ulteriorly increase 2'-FL production. Initially, a modular pathway engineering was strengthened to balance the synthesis pathway through different plasmid combinations with a resulting maximum 2'-FL titre of 1.45 g l-1 . To further facilitate the metabolic flux from GDP-l-fucose towards 2'-FL, the CRISPR-Cas9 system was utilized to inactivate the genes including lacZ and wcaJ, increasing the titre by 6.59-fold. Notably, the co-introduction of NADPH and GTP regeneration pathways was confirmed to be more conducive to 2'-FL formation, achieving a 2'-FL titre of 2.24 g l-1 . Moreover, comparisons of various exogenous α1,2-fucosyltransferase candidates revealed that futC from Helicobacter pylori generated the highest titre of 2'-FL. Finally, the viability of scaled-up production of 2'-FL was evidenced in a 3 l bioreactor with a maximum titre of 22.3 g l-1 2'-FL and a yield of 0.53 mole 2'-FL mole-1 lactose.

biotechnology & applied microbiology,microbiology
Efficient production of 2′-fucosyllactose from fructose through metabolically engineered recombinant Escherichia coli

Ran You,Lei Wang,Meirong Hu,Yong Tao

DOI: https://doi.org/10.1186/s12934-024-02312-5

IF: 6.352

2024-02-02

Microbial Cell Factories

Abstract:The biosynthesis of human milk oligosaccharides (HMOs) using several microbial systems has garnered considerable interest for their value in pharmaceutics and food industries. 2′-Fucosyllactose (2′-FL), the most abundant oligosaccharide in HMOs, is usually produced using chemical synthesis with a complex and toxic process. Recombinant E. coli strains have been constructed by metabolic engineering strategies to produce 2′-FL, but the low stoichiometric yields (2′-FL/glucose or glycerol) are still far from meeting the requirements of industrial production. The sufficient carbon flux for 2′-FL biosynthesis is a major challenge. As such, it is of great significance for the construction of recombinant strains with a high stoichiometric yield.

biotechnology & applied microbiology
High-titer de novo biosynthesis of the predominant human milk oligosaccharide 2' fucosyllactose from sucrose in Escherichia coli.

K. Parschat,Benedikt Engels,Dirk Wartenberg,S. Jennewein,Sandra Schreiber

DOI: https://doi.org/10.1021/acssynbio.0c00304

IF: 5.249

2020-09-23

ACS Synthetic Biology

Abstract:Human milk oligosaccharides (HMOs) are unique components of human breastmilk. Their large-scale production by fermentation allows infant formulae to be fortified with HMOs, but current fermentation processes require lactose as a starting material, increasing the costs, bioburden, and environmental impact of manufacturing. Here we report the development of an Escherichia coli strain that produces 2'-fucosyllactose (2'-FL), the most abundant HMO, de novo using sucrose as the sole carbon source. Strain engineering required the expression of a novel glucose-accepting galactosyltransferase, overexpression of the de novo UDP-D-galactose and GDP-L-fucose pathways, the engineering of an intracellular pool of free glucose, and overexpression of a suitable α(1,2)-fucosyltransferase. The export of 2' FL was facilitated using a sugar efflux transporter. The final production strain achieved 2'-FL yields exceeding 60 g/L after fermentation for 84 h. This efficient strategy facilitates the lactose-independent production of HMOs by fermentation, which will improve product quality and reduce the costs of manufacturing.

Chemistry,Medicine,Biology
Engineering the Substrate Transport and Cofactor Regeneration Systems for Enhancing 2′-Fucosyllactose Synthesis in Bacillus subtilis

Jieying Deng,Liuyan Gu,Taichi Chen,Hao Huang,Xiaoqiang Yin,Xueqin Lv,Yanfeng Liu,Nan Li,Zhenmin Liu,Jianghua Li,Guocheng Du,Long Liu

DOI: https://doi.org/10.1021/acssynbio.9b00314

IF: 5.249

2019-09-24

ACS Synthetic Biology

Abstract:Human milk oligosaccharides (HMOs) have been proven to be beneficial to infants' intestinal health and immune systems. 2′-Fucosyllactose (2′-FL) is the most abundant and thoroughly studied HMO and has been approved to be an additive of infant formula. How to construct efficient and safe microbial cell factories for the production of 2′-FL attracts increasing attention. In this work, we engineered the Bacillus subtilis as an efficient 2′-FL producer by engineering the substrate transport and cofactor guanosine 5′-triphosphate (GTP) regeneration systems. First, we constructed a synthesis pathway for the 2′-FL precursor guanosine 5′-diphosphate-l-fucose (GDP-l-fucose) by introducing the salvage pathway gene fkp from Bacteriodes fragilis and improved the fucose importation by overexpressing the transporters. Then, the complete synthesis pathway of 2′-FL was constructed by introducing the heterologous fucosyltransferases from different sources, and it was found that the gene from Helicobacter pylori was the best one for 2′-FL synthesis. We also improved the substrate lactose importation by introducing heterologous lactose permeases and eliminated endogenous β-galactosidase (yesZ) to block the lactose degradation. Next, the production of 2′-FL and GDP-l-fucose was improved by fine-tuning the expression of cofactor guanosine 5′-triphosphate regeneration module genes gmd, ndk, guaA, guaC, ykfN, deoD, and xpt. Finally, a 3 L fed-batch fermentation was performed, and the highest 2′-FL titer reached 5.01 g/L with a yield up to 0.85 mol/mol fucose. We optimized the synthesis modules of 2′-FL in B. subtilis, and this provides a good starting point for metabolic engineering to further improve 2′-FL production in the future.

biochemical research methods
High-Level De Novo Biosynthesis of 2′-Fucosyllactose by Metabolically Engineered Escherichia coli

Yuanlin Liu,Yingying Zhu,Li Wan,Roulin Chen,Wenli Zhang,Wanmeng Mu

DOI: https://doi.org/10.1021/acs.jafc.2c02484

IF: 6.1

2022-07-14

Journal of Agricultural and Food Chemistry

Abstract:2'-Fucosyllactose (2'-FL) is the most abundant oligosaccharide in human milk. In this study, a highly efficient biosynthetic route for 2'-FL production was designed via the de novo pathway of GDP-l-fucose using engineered Escherichia coli BL21(DE3). Specifically, plasmid-based strains with previously deleted lacZ and wcaJ were further reconstructed by introducing de novo pathway genes and α1,2-fucosyltransferase-encoding wbgL to realize 2'-FL synthesis. The 2'-FL titer was enhanced to 3.92 g/L by further introducing rcsA and rcsB. Subsequently, the additional wbgL expression cassette was chromosomally integrated into recA locus to strengthen fucosylation reaction and a strong constitutive promoter (PJ23119) was used to replace the original promoters of manC-manB and gmd-wcaG to improve 2'-FL synthesis. The maximal 2'-FL titer reached 9.06 and 79.23 g/L in shake-flask and fed-batch cultivation, respectively. The 2'-FL productivity reached 1.45 g/L/h, showing remarkable production potential in large-scale industrial application.

food science & technology,chemistry, applied,agriculture, multidisciplinary
[Minimally invasive heart surgery--a fad or a clinically recognized therapy method?].

H. Reichenspurner,D. Boehm,A. Welz,B. Reichart

Zeitschrift für Kardiologie

Abstract:Within the last 5 years new less invasive surgical techniques have been developed in the field of cardiac surgery. This new field named "minimally invasive cardiac surgery" can be subdivided into techniques which do not require cardiopulmonary bypass and are used mainly for coronary artery surgery (called minimally invasive direct coronary artery surgery, MIDCAB technique). This MIDCAB procedure can be done through a small left anterior thoracotomy or a sternotomy. In addition there are other methods which allow the performance of complex cardiac surgery through small accesses in combination with the use of an endovascular CPB system and internal aortic clamping to achieve cardioplegic arrest (so-called Port-Access method). Also for valvular surgery, new surgical techniques were developed allowing access to mitral and aortic valves through limited incisions. In addition, new less invasive techniques were developed for congenital heart surgery. This article will describe the various surgical techniques and define the indications for minimally invasive cardiac surgery.
The genome of poliovirus is an exceptional eukaryotic mRNA.

Y. Lee,A. Nomoto,E. Wimmer

DOI: https://doi.org/10.1016/S0079-6603(08)60910-1

Progress in Nucleic Acid Research and Molecular Biology

Abstract:
Pathway Optimization of 2′-Fucosyllactose Production in Engineered Escherichia coli

Wen Li,Yingying Zhu,Li Wan,Cuie Guang,Wanmeng Mu

DOI: https://doi.org/10.1021/acs.jafc.0c07224

IF: 6.1

2021-01-26

Journal of Agricultural and Food Chemistry

Abstract:2′-Fucosyllactose (2′-FL), one of the most valuable oligosaccharides in human milk, is used as an emerging food ingredient in the nutraceutical and food industries due to its numerous health benefits. Herein, the de novo and salvage pathways for GDP-fucose synthesis were engineered and optimized in Escherichia coli BL21 (DE3) to improve the production of 2′-FL. The de novo pathway genes encoding phosphomannomutase (ManB), mannose-1-phosphate guanyltransferase (ManC), GDP-d-mannose-4,6-dehydratase (Gmd), and GDP-l-fucose synthase (WcaG) combined with the gene from the salvage pathway encoding fucose kinase/fucose-1-phosphate guanylyltransferase (Fkp) were reconstructed in two vectors to evaluate the GDP-fucose biosynthesis. Then, the fucT2 gene, encoding α1,2-fucosyltransferase, was introduced into the GDP-fucose-overproducing strains to realize 2′-FL biosynthesis. Furthermore, the genes in bypass pathways, including lacZ, fucI, fucK, and wcaJ, were inactivated to improve 2′-FL production. In addition, the two GDP-fucose synthesis pathways, along with fucT2, were transcriptionally fine-tuned to efficiently increase 2′-FL production. The final metabolically engineered E. coli produced 2.62 and 14.1 g/L in shake-flask and fed-batch cultivations, respectively.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jafc.0c07224?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jafc.0c07224</a>.Primers, gene-editing plasmids and DNA templates, and gene-editing primers used in this study (<a class="ext-link" href="/doi/suppl/10.1021/acs.jafc.0c07224/suppl_file/jf0c07224_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

food science & technology,chemistry, applied,agriculture, multidisciplinary
ATM-Dependent Phosphorylation of All Three Members of the MRN Complex: From Sensor to Adaptor

M. Lavin,S. Kozlov,M. Gatei,A. Kijas

DOI: https://doi.org/10.3390/biom5042877

IF: 6.064

2015-10-23

Biomolecules

Abstract:The recognition, signalling and repair of DNA double strand breaks (DSB) involves the participation of a multitude of proteins and post-translational events that ensure maintenance of genome integrity. Amongst the proteins involved are several which when mutated give rise to genetic disorders characterised by chromosomal abnormalities, cancer predisposition, neurodegeneration and other pathologies. ATM (mutated in ataxia-telangiectasia (A-T) and members of the Mre11/Rad50/Nbs1 (MRN complex) play key roles in this process. The MRN complex rapidly recognises and locates to DNA DSB where it acts to recruit and assist in ATM activation. ATM, in the company of several other DNA damage response proteins, in turn phosphorylates all three members of the MRN complex to initiate downstream signalling. While ATM has hundreds of substrates, members of the MRN complex play a pivotal role in mediating the downstream signalling events that give rise to cell cycle control, DNA repair and ultimately cell survival or apoptosis. Here we focus on the interplay between ATM and the MRN complex in initiating signaling of breaks and more specifically on the adaptor role of the MRN complex in mediating ATM signalling to downstream substrates to control different cellular processes.
Multi-Path Optimization for Efficient Production of 2′-Fucosyllactose in an Engineered Escherichia coli C41 (DE3) Derivative

Zhijian Ni,Zhongkui Li,Jinyong Wu,Yuanfei Ge,Yingxue Liao,Lixia Yuan,Xiangsong Chen,Jianming Yao

DOI: https://doi.org/10.3389/fbioe.2020.611900

IF: 5.7

2020-12-03

Frontiers in Bioengineering and Biotechnology

Abstract:2′-fucosyllactose (2′-FL), one of the simplest but most abundant oligosaccharides in human milk, has been demonstrated to have many positive benefits for the healthy development of newborns. However, the high-cost production and limited availability restrict its widespread use in infant nutrition and further research on its potential functions. In this study, on the basis of previous achievements, we developed a powerful cell factory by using a lacZ -mutant Escherichia coli C41 (DE3)ΔZ to ulteriorly increase 2′-FL production by feeding inexpensive glycerol. Initially, we co-expressed the genes for GDP-L-fucose biosynthesis and heterologous α-1,2-fucosyltransferase in C41(DE3)ΔZ through different plasmid-based expression combinations, functionally constructing a preferred route for 2′-FL biosynthesis. To further boost the carbon flux from GDP-L-fucose toward 2′-FL synthesis, deletion of chromosomal genes ( wcaJ, nudD , and nudK ) involved in the degradation of the precursors GDP-L-fucose and GDP-mannose were performed. Notably, the co-introduction of two heterologous positive regulators, RcsA and RcsB, was confirmed to be more conducive to GDP-L-fucose formation and thus 2′-FL production. Further a genomic integration of an individual copy of α-1,2-fucosyltransferase gene, as well as the preliminary optimization of fermentation conditions enabled the resulting engineered strain to achieve a high titer and yield. By collectively taking into account the intracellular lactose utilization, GDP-L-fucose availability, and fucosylation activity for 2′-FL production, ultimately a highest titer of 2′-FL in our optimized conditions reached 6.86 g/L with a yield of 0.92 mol/mol from lactose in the batch fermentation. Moreover, the feasibility of mass production was demonstrated in a 50-L fed-batch fermentation system in which a maximum titer of 66.80 g/L 2′-FL was achieved with a yield of 0.89 mol 2′-FL/mol lactose and a productivity of approximately 0.95 g/L/h 2′-FL. As a proof of concept, our preliminary 2′-FL production demonstrated a superior production performance, which will provide a promising candidate process for further industrial production.

multidisciplinary sciences
Metabolic engineering of Escherichia coli for the production of 2′-fucosyllactose and 3-fucosyllactose through modular pathway enhancement

Di Huang,Kexin Yang,Jia Liu,Yingying Xu,Yuanyuan Wang,Ru Wang,Bin Liu,Lu Feng

DOI: https://doi.org/10.1016/j.ymben.2017.03.001

IF: 8.4

2017-05-01

Metabolic Engineering

Abstract:Fucosyllactoses, including 2'-fucosyllactose (2'-FL) and 3-fucosyllactose (3-FL), are important oligosaccharides in human milk that are commonly used as nutritional additives in infant formula due to their biological functions, such as the promotion of bifidobacteria growth, inhibition of pathogen infection, and improvement of immune response. In this study, we developed a synthetic biology approach to promote the efficient biosynthesis of 2'-FL and 3-FL in engineered Escherichia coli. To boost the production of 2'-FL and 3-FL, multiple modular optimization strategies were applied in a plug-and-play manner. First, comparisons of various exogenous α1,2-fucosyltransferase and α1,3-fucosyltransferase candidates, as well as a series of E. coli host strains, demonstrated that futC and futA from Helicobacter pylori using BL21(DE3) as the host strain yielded the highest titers of 2'-FL and 3-FL. Subsequently, both the availability of the lactose acceptor substrate and the intracellular pool of the GDP-L-fucose donor substrate were optimized by inactivating competitive (or repressive) pathways and strengthening acceptor (or donor) availability to achieve overproduction. Moreover, the intracellular redox regeneration pathways were engineered to further enhance the production of 2'-FL and 3-FL. Finally, various culture conditions were optimized to achieve the best performance of 2'-FL and 3-FL biosynthesizing strains. The final concentrations of 2'-FL and 3-FL were 9.12 and 12.43g/L, respectively. This work provides a platform that enables modular construction, optimization and characterization to facilitate the development of FL-producing cell factories.

biotechnology & applied microbiology
Efficient Biosynthesis of Difucosyllactose via De Novo GDP-l-Fucose Pathway in Metabolically Engineered Escherichia coli

Shanquan Liang,Zi He,Dan Liu,Shaoqing Yang,Qiaojuan Yan,Zhengqiang Jiang

DOI: https://doi.org/10.1021/acs.jafc.3c09742

2024-02-28

Abstract:Difucosyllactose (DFL) is an important component of human milk oligosaccharides (HMOs) and has significant benefits for the growth and development of infants. So far, a few microbial cell factories have been constructed for the production of DFL, which still have problems of low production and high cost. Herein, a high-level de novo pathway DFL-producing strain was constructed by multistep optimization strategies in Escherichia coli BL21star(DE3). We first efficiently synthesized the intermediate 2'-fucosyllactose (2'-FL) in E. coli BL21star(DE3) by the advisable stepwise strategy. The truncated α-1,3/4-fucosyltransferase (Hp3/4FT) was then introduced into the engineered strain to achieve de novo biosynthesis of DFL. ATP-dependent protease (Lon) and GDP-mannose hydrolase (NudK) were deleted, and mannose-6-phosphate isomerase (ManA) was overexpressed to improve GDP-l-fucose accumulation. The regulator RcsA was overexpressed to fine-tune the expression level of pathway genes, thereby increasing the synthesis of DFL. The final strain produced 6.19 g/L of DFL in the shake flask and 33.45 g/L of DFL in the 5 L fermenter, which were the highest reported titers so far. This study provides a more economical, sustainable, and effective strategy to produce the fucosylated human milk oligosaccharides (HMOs).
Engineering Escherichia coli MG1655 for Highly Efficient Biosynthesis of 2'-Fucosyllactose by De Novo GDP-Fucose Pathway

Roulin Chen,Yingying Zhu,Hao Wang,Yuanlin Liu,Jiawei Meng,Yihan Chen,Wanmeng Mu

DOI: https://doi.org/10.1021/acs.jafc.3c05052

2023-10-11

Abstract:2'-Fucosyllactose (2'-FL), the most typical human milk oligosaccharide, is used as an additive in premium infant formula. Herein, we constructed two highly effective 2'-FL synthesis producers via a de novo GDP-fucose pathway from engineered Escherichia coli MG1655. First, lacZ and wcaJ, two competitive pathway genes, were disrupted to block the invalid consumption of lactose and GDP-fucose, respectively. Next, the lacY gene was strengthened by switching its native promoter to PJ23119. To enhance the supply of endogenous GDP-fucose, the promoters of gene clusters manC-manB and gmd-fcl were strengthened individually or in combination. Subsequently, chromosomal integration of a constitutive PJ23119 promoter-based BKHT expression cassette (PJ23119-BKHT) was performed in the arsB and recA loci. The most productive plasmid-based and plasmid-free strains produced 76.9 and 50.1 g/L 2'-FL by fed-batch cultivation, respectively. Neither of them generated difucosyl lactose nor 3-fucosyllactose as byproducts.
Engineered Bacillus subtilis for the de novo production of 2′-fucosyllactose

Quanwei Zhang,Zhenmin Liu,Hongzhi Xia,Ziyang Huang,Yonglian Zhu,Linfeng Xu,Yanfeng Liu,Jianghua Li,Guocheng Du,Xueqin Lv,Long Liu

DOI: https://doi.org/10.1186/s12934-022-01838-w

IF: 6.352

2022-06-03

Microbial Cell Factories

Abstract:The most abundant human milk oligosaccharide in breast milk, 2′-fucosyllactose (2′-FL), has been approved as an additive to infant formula due to its multifarious nutraceutical and pharmaceutical functions in promoting neonate health. However, the low efficiency of de novo synthesis limits the cost-efficient bioproduction of 2′-FL.

biotechnology & applied microbiology
Enhanced production of 2'-fucosyllactose in engineered Escherichia coli BL21star(DE3) by modulation of lactose metabolism and fucosyltransferase

Young-Wook Chin,Ji-Yeong Kim,Won-Heong Lee,Jin-Ho Seo

DOI: https://doi.org/10.1016/j.jbiotec.2015.06.431

2015-09-20

Abstract:2'-Fucosyllactose (2-FL) is one of most abundant functional oligosaccharides in human milk, which is involved in many biological functions for human health. To date, most microbial systems for 2-FL production have been limited to use Escherichia coli JM strains since they cannot metabolize lactose. In this study, E. coli BL21star(DE3) was engineered through deletion of the whole endogenous lactose operon and introduction of the modified lactose operon containing lacZ△M15 from E. coli K-12. Expression of genes for guanosine 5'-diphosphate (GDP)-l-fucose biosynthetic enzymes and heterologous α-1,2-fucosyltransferase (FucT2) from Helicobacter pylori allowed the engineered E. coli BL21star(DE3) to produce 2-FL with 3-times enhanced yield than the non-engineered E. coli BL21star(DE3). In addition, the titer and yield of 2-FL were further improved by adding the three aspartate molecules at the N-terminal of FucT2. Overall, 6.4 g/L 2-FL with the yield of 0.225 g 2-FL/g lactose was obtained in fed-batch fermentation of the engineered E. coli BL21star(DE3) expressing GDP-l-fucose biosynthetic enzymes and three aspartate tagged FucT2.
Recent advances and challenges in microbial production of human milk oligosaccharides

Jieying Deng,Xueqin Lv,Jianghua Li,Guocheng Du,Jian Chen,Long Liu

DOI: https://doi.org/10.1007/s43393-020-00004-w

2020-06-30

Systems Microbiology and Biomanufacturing

Abstract:Human milk oligosaccharides (HMOs) are one of the major differences between livestock milk and human milk, and the prebiotic functions of HMOs have been verified through in vitro and clinical trials. The most abundant HMOs include 2′-fucysollactose (2′-FL), 3-fucosyllactose (3-FL), lacto-N-neotetraose (LNnT) and lacto-N-tetraose (LNT); their application and synthesis have attracted wide attentions. In recent years, the biotechnological production of 2′-FL, 3-FL, LNnT and LNT have emerged based on techniques such as whole-cell catalysis and fermentation. In particular, the development of metabolic engineering and synthetic biology methods and strategies have facilitated efficient biosynthesis of these HMOs. However, these advantages have not been systematically reviewed yet. In this review, we first discuss the structures and applications of HMOs; secondly, strategies of microbial synthesis of the most abundant 2′-FL, 3-FL, LNnT and LNT are summarized and compared. Finally, challenges and perspectives of efficient microbial production of HMOs as well as strategies for overcoming the challenges are discussed. This review reveals the whole picture of recent development in HMOs microbial synthesis and can further facilitate the understanding of limiting factors, and further propose a few directions to promote the development of efficient production hosts.
Production of a human milk oligosaccharide 2′-fucosyllactose by metabolically engineered Saccharomyces cerevisiae

Sora Yu,Jing-Jing Liu,Eun Ju Yun,Suryang Kwak,Kyoung Heon Kim,Yong-Su Jin

DOI: https://doi.org/10.1186/s12934-018-0947-2

IF: 6.352

2018-06-27

Microbial Cell Factories

Abstract:Background2′-Fucosyllactose (2-FL), one of the most abundant oligosaccharides in human milk, has potential applications in foods due to its health benefits such as the selective promotion of bifidobacterial growth and the inhibition of pathogenic microbial binding to the human gut. Owing to the limited amounts of 2-FL in human milk, alternative microbial production of 2-FL is considered promising. To date, microbial production of 2-FL has been studied mostly in Escherichia coli. In this study, 2-FL was produced alternatively by using a yeast Saccharomyces cerevisiae, which may have advantages over E. coli.ResultsFucose and lactose were used as the substrates for the salvage pathway which was constructed with fkp coding for a bifunctional enzyme exhibiting l-fucokinase and guanosine 5′-diphosphate-l-fucose phosphorylase activities, fucT2 coding for α-1,2-fucosyltransferase, and LAC12 coding for lactose permease. Production of 2-FL by the resulting engineered yeast was verified by mass spectrometry. 2-FL titers of 92 and 503 mg/L were achieved from 48-h batch fermentation and 120-h fed-batch fermentation fed with ethanol as a carbon source, respectively.ConclusionsThis is the first report on 2-FL production by using yeast S. cerevisiae. These results suggest that S. cerevisiae can be considered as a host engineered for producing 2-FL via the salvage pathway.

biotechnology & applied microbiology
Metabolic Engineering of De Novo Pathway for the Production of 2′-Fucosyllactose in Escherichia coli

Chenchen Li,Mengli Li,Miaomiao Hu,Tao Zhang

DOI: https://doi.org/10.1007/s12033-023-00657-7

2023-01-19

Molecular Biotechnology

Abstract:2′-Fucosyllactose (2′-FL), one of the most abundant oligosaccharides in human milk, has gained increased attention owing to its nutraceutical and pharmaceutical potential. However, limited availability and high-cost of preparation have limited its widespread application and in-depth investigation of its potential functions. Here, a modular pathway engineering was implemented to construct an Escherichia coli strain to improve the biosynthesis titer of 2′-FL. Before overexpression of manB , manC , gmd , wcaG , and heterologous expression of futC , genes wcaJ and lacZ encoding UDP-glucose lipid carrier transferase and β-galactosidase, respectively, were inactivated from E. coli BL21 (DE3) with the CRISPR-Cas9 system, which inhibited the production of 2′-FL. The results showed that final shake flask culture yielded a 3.8-fold increase in 2′-FL (0.98 g/L) from the engineered strain ELC07. Fed-batch fermentation conditions were optimized in a 3-L bioreactor. The highest titer of 2′-FL (18.22 g/L) was obtained, corresponding to a yield of 0.25 g/g glycerol and a substrate conversion of 0.88 g/g lactose.

biochemistry & molecular biology,biotechnology & applied microbiology

Passengers' injuries reflected carriage interior at the railway accident in Mundelstrup, Denmark.

Biotechnological Production of 2′-Fucosyllactose: A Prevalent Fucosylated Human Milk Oligosaccharide

Recent advances on 2'-fucosyllactose: physiological properties, applications, and production approaches

Metabolic engineering strategies of de novo pathway for enhancing 2′‐fucosyllactose synthesis in Escherichia coli

Efficient production of 2′-fucosyllactose from fructose through metabolically engineered recombinant Escherichia coli

High-titer de novo biosynthesis of the predominant human milk oligosaccharide 2' fucosyllactose from sucrose in Escherichia coli.

Engineering the Substrate Transport and Cofactor Regeneration Systems for Enhancing 2′-Fucosyllactose Synthesis in Bacillus subtilis

High-Level De Novo Biosynthesis of 2′-Fucosyllactose by Metabolically Engineered Escherichia coli

[Minimally invasive heart surgery--a fad or a clinically recognized therapy method?].

The genome of poliovirus is an exceptional eukaryotic mRNA.

Pathway Optimization of 2′-Fucosyllactose Production in Engineered Escherichia coli

ATM-Dependent Phosphorylation of All Three Members of the MRN Complex: From Sensor to Adaptor

Multi-Path Optimization for Efficient Production of 2′-Fucosyllactose in an Engineered Escherichia coli C41 (DE3) Derivative

Metabolic engineering of Escherichia coli for the production of 2′-fucosyllactose and 3-fucosyllactose through modular pathway enhancement

Efficient Biosynthesis of Difucosyllactose via De Novo GDP-l-Fucose Pathway in Metabolically Engineered Escherichia coli

Engineering Escherichia coli MG1655 for Highly Efficient Biosynthesis of 2'-Fucosyllactose by De Novo GDP-Fucose Pathway

Engineered Bacillus subtilis for the de novo production of 2′-fucosyllactose

Enhanced production of 2'-fucosyllactose in engineered Escherichia coli BL21star(DE3) by modulation of lactose metabolism and fucosyltransferase

Recent advances and challenges in microbial production of human milk oligosaccharides

Production of a human milk oligosaccharide 2′-fucosyllactose by metabolically engineered Saccharomyces cerevisiae

Metabolic Engineering of De Novo Pathway for the Production of 2′-Fucosyllactose in Escherichia coli